NDAINTRAVENOUSPOWDER
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
MICAFUNGIN (micafungin) by Pfizer is [see microbiology ()] . Approved for candidemia, candidiasis, invasive candidiasis and 1 more indications. First approved in 2021.
Drug data last refreshed 19h ago
Mechanism of Action
[see Microbiology ()] .
Indications (4)
Worked on MICAFUNGIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.